Last reviewed · How we verify
Maraviroc (Celsentri)
Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.
Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus, HIV-1 infection in treatment-naïve patients with CCR5-tropic virus.
At a glance
| Generic name | Maraviroc (Celsentri) |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | CCR5 antagonist |
| Target | CCR5 (C-C chemokine receptor type 5) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Maraviroc is a selective antagonist of the CCR5 co-receptor, which HIV uses alongside CD4 to gain entry into host cells. By binding to CCR5 and blocking its interaction with HIV envelope proteins, the drug prevents viral attachment and fusion with the cell membrane. This mechanism is effective only against CCR5-tropic (R5) HIV strains, not X4-tropic variants.
Approved indications
- HIV-1 infection in treatment-experienced patients with CCR5-tropic virus
- HIV-1 infection in treatment-naïve patients with CCR5-tropic virus
Common side effects
- Upper respiratory tract infection
- Cough
- Pyrexia
- Rash
- Abdominal pain
- Diarrhea
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Antiviral Clinical Trial for Long Covid-19 (PHASE2)
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1, PHASE2)
- This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction (PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (NA)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |